Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Shares Outstanding (Weighted Average) (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Shares Outstanding (Weighted Average) readings, the most recent being $99.5 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) fell 0.9% to $99.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $99.5 million, a 0.9% decrease, with the full-year FY2025 number at $99.5 million, down 0.9% from a year prior.
  • Shares Outstanding (Weighted Average) hit $99.5 million in Q4 2025 for Neurocrine Biosciences, roughly flat from $99.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $101.1 million in Q3 2024 to a low of $94.2 million in Q1 2021.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $97.6 million (2023), compared with a mean of $97.5 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): increased 3.49% in 2024 and later dropped 1.79% in 2025.
  • Neurocrine Biosciences' Shares Outstanding (Weighted Average) stood at $94.6 million in 2021, then rose by 1.27% to $95.8 million in 2022, then increased by 1.98% to $97.7 million in 2023, then rose by 2.76% to $100.4 million in 2024, then fell by 0.9% to $99.5 million in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $99.5 million (Q4 2025), $99.3 million (Q3 2025), and $99.0 million (Q2 2025) per Business Quant data.